Key result
Rosuvastatin achieves ~/dL lower LDL-C at 12 months compared to atorvastatin in dyslipidemia.
Why the study?
Although atorvastatin and rosuvastatin effectively reduce LDL-C and cardiovascular risk, comparative evidence on their efficacy, safety, tolerability, and compliance from routine clinical practice in the Indian population was limited.
Does rosuvastatin monotherapy produce a greater reduction in LDL cholesterol compared to atorvastatin monotherapy over 12 months in adult patients with dyslipidemia?
Cohort (n=300)
Simple randomization based on assigned reference number (odd-numbered receiving atorvastatin, even-numbered receiving rosuvastatin)
No
Does rosuvastatin monotherapy produce a greater reduction in LDL cholesterol compared to atorvastatin monotherapy over 12 months in adult patients with dyslipidemia?
In Indian patients with dyslipidemia, rosuvastatin (10–20 mg/day) provides superior reductions in LDL-C and triglycerides and greater increases in HDL-C over 12 months with fewer adverse event discontinuations than atorvastatin (20–40 mg/day), though it causes a more pronounced rise in HbA1c.
Answers are grounded in this paper and cite their sources.
Rosuvastatin was associated with modestly lower LDL-C at 12 months; hypothesis-generating for statin selection in dyslipidemia and requires randomized confirmation.
Background: Dyslipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease and contributes substantially to global morbidity and mortality. It commonly coexists with hypertension and type 2 diabetes mellitus, thereby accelerating the development of cardiovascular complications. Statins remain the cornerstone of lipid-lowering therapy, with atorvastatin and rosuvastatin being among the most frequently prescribed agents. Although both drugs effectively reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk, comparative evidence from routine clinical practice in the Indian population remains limited. Aim: To comparatively evaluate the efficacy, safety, tolerability, and treatment compliance of rosuvastatin and atorvastatin monotherapy in patients with dyslipidemia, including those with associated hypertension and/or type 2 diabetes mellitus, managed at a tertiary care hospital according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines. Materials and Methods: A prospective observational comparative study was conducted in the Departments of Pharmacology and Medicine at Hamdard Institute of Medical Sciences and Research (HIMSR) and Hakeem Abdul Hameed Centenary Hospital (HAHC), Jamia Hamdard, New Delhi. A total of 300 eligible patients with dyslipidemia were enrolled, of whom 291 completed the study, while nine patients were lost to follow-up. Participants received either rosuvastatin or atorvastatin monotherapy according to the treating physician's clinical judgment. Baseline demographic characteristics, cardiovascular risk factors, lipid profile parameters, fasting blood glucose, glycated haemoglobin (HbA1c), serum creatinine, blood urea, serum glutamic-pyruvic transaminase (SGPT), treatment compliance, and adverse drug reactions were assessed at baseline and during follow-up. Statistical analysis was performed using appropriate parametric and non-parametric tests, with p < 0.05 considered statistically significant. Results: Among the 300 enrolled participants, 291 completed follow-up. Both rosuvastatin and atorvastatin produced significant improvements in serum lipid parameters during the study period. Rosuvastatin demonstrated greater reductions in total cholesterol and LDL cholesterol and achieved lipid targets in a higher proportion of patients, whereas atorvastatin showed comparable improvement in triglyceride levels. Both treatments were generally well tolerated, with adverse drug reactions being mild and consistent with the established safety profile of statins. Patient compliance remained satisfactory throughout the study. Conclusion: Rosuvastatin and atorvastatin are both effective and well-tolerated treatment options for dyslipidemia. Rosuvastatin demonstrated comparatively greater efficacy in improving LDL cholesterol and overall lipid control, while maintaining a favourable safety profile. These findings support the use of rosuvastatin as an effective therapeutic option for achieving recommended lipid targets in patients with dyslipidemia, particularly those with associated cardiovascular risk factors.
No takes yet. Share an insight, caveat, or question.
Shourie et al. (2026) conducted a cohort in Dyslipidemia (n=300). Rosuvastatin vs. Atorvastatin 20–40 mg/day was evaluated on Mean LDL cholesterol (mg/dL) at 12 months (p=0.018). Rosuvastatin achieved lower mean LDL-C at 12 months compared to atorvastatin in adults with dyslipidemia.
Synapse has enriched 10 related papers. Consider them for comparative context: